

TESI DOCTORAL

**CARACTERITZACIÓ DE LA RESPOSTA DE CÈL·LULES
TUMORALS A LES MITRAMICINES**

Marc Bataller Chardi
Barcelona, maig de 2009

BIBLIOGRAFIA.

7. BIBLIOGRAFIA.

Abend M. (2003). Reasons to reconsider the significance of apoptosis for cancer therapy, *Int. J. Radiat. Biol.* 79, 927-41.

Albertini V, Jain A, Vignati S, Napoli S, Rinaldi A, Kwee I, Nur-e-Alam M, Bergant J, Bertoni F, Carbone GM, Rohr J and Catapano CV. (2006). Novel GC-rich DNA-binding compound produced by a genetically engineered mutant of the mithramycin producer *Streptomyces argillaceus* exhibits improved transcriptional repressor activity: implications for cancer therapy, *Nucleic Acids Res.* 34, 1721-1734.

Alcorta DA, Xiong Y, Phelps D, Hannon G, Beach D and Barrett JC. (1996). Involvement of the cyclin-dependent kinase inhibitor p16 (INK4a) in replicative senescence of normal human fibroblasts, *Proc. Natl. Acad. Sci. U S A* 93, 13742-13747.

Andreassen PR, Lacroix FB, Lohez OD and Margolis RL. (2001). Neither p21^{WAF1} nor 14-3-3 σ prevents G2 progression to mitotic catastrophe in human colon carcinoma cells after DNA damage, but p21^{WAF1} induces stable G1 arrest in resulting tetraploid cells, *Cancer Res.* 61, 7660-7668.

Ashwell S and Zabludoff S. (2008). DNA damage detection and repair pathways--recent advances with inhibitors of checkpoint kinases in cancer therapy, *Clin. Cancer Res.* 14, 4032-4037.

Barceló F, Scotta C, Ortiz-Lombardia M, Méndez C, Salas JA and Portugal J. (2007). Entropically-driven binding of mithramycin in the minor groove of C/G-rich DNA sequences, *Nucleic Acids Res.* 35, 2215-2226.

Bataller M, Mendez C, Salas JA and Portugal J. (2008). Mithramycin SK modulates polyploidy and cell death in colon carcinoma cells, *Mol. Cancer Ther.* 7, 2988-2997.

Bataller M and Portugal J. (2005). Apoptosis and cell recovery in response to oxidative stress in p53-deficient prostate carcinoma cells, *Arch. Biochem. Biophys.* 437, 151-158.

Baus F, Gire V, Fisher D, Piette J and Dulic V. (2003). Permanent cell cycle exit in G2 phase after DNA damage in normal human fibroblasts, *EMBO J.* 22, 3992-4002.

Bernards R, Shackleford GM, Gerber MR, Horowitz JM, Friend SH, Schartl M, Bogenmann E, Rapaport JM, McGee T, Dryja TP and et al. (1989). Structure and expression of the murine retinoblastoma gene and characterization of its encoded protein, *Proc. Natl. Acad. Sci. U S A* 86, 6474-6478.

Biroccio A, Amodei S, Antonelli A, Benassi B and Zupi G. (2003). Inhibition of c-Myc oncoprotein limits the growth of human melanoma cells by inducing cellular crisis, *J. Biol. Chem.* 278, 35693-35701.

Blagosklonny MV. (2007). Mitotic arrest and cell fate: why and how mitotic inhibition of transcription drives mutually exclusive events, *Cell Cycle* 6, 70-74.

Blume SW, Snyder RC, Ray R, Thomas S, Koller CA and Miller DM. (1991). Mithramycin inhibits Sp1 binding and selectively inhibits transcriptional activity of the dihydrofolate reductase gene in vitro and in vivo, *J. Clin. Invest.* 88, 1613-1621.

Boatright KM and Salvesen GS. (2003). Mechanisms of caspase activation, *Curr. Opin. Cell Biol.* 15, 725-731.

Borgne A, Versteeg I, Mahe M, Studeny A, Leonce S, Naime I, Rodriguez M, Hickman JA, Meijer L and Golsteyn RM. (2006). Analysis of cyclin B1 and CDK activity during apoptosis induced by camptothecin treatment, *Oncogene* 25, 7361-7372.
Bree RT, Stenson-Cox C, Grealy M, Byrnes L, Gorman AM and Samali A. (2002). Cellular longevity: role of apoptosis and replicative senescence, *Biogerontology* 3, 195-206.

Broude EV, Demidenko ZN, Vivo C, Swift ME, Davis BM, Blagosklonny MV and Roninson IB. (2007). p21 (CDKN1A) is a negative regulator of p53 stability, *Cell Cycle* 6, 1468-1471.

Brown JM. (1997). NCI's anticancer drug screening program may not be selecting for clinically active compounds, *Oncol Res.* 9, 213-215.

Brown JM and Attardi LD. (2005). The role of apoptosis in cancer development and treatment response, *Nature Rev. Cancer* 5, 231-237.

Bunz F, Dutriaux A, Lengauer C, Waldman T, Zhou S, Brown JP, Sedivy JM, Kinzler KW and Vogelstein B. (1998). Requirement for p53 and p21 to sustain G₂ arrest after DNA damage, *Science* 282, 1497-1501.

Bunz F, Hwang PM, Torrance C, Waldman T, Zhang Y, Dillehay L, Williams J, Lengauer C, Kinzler KW and Vogelstein B. (1999). Disruption of p53 in human cancer cells alters the responses to therapeutic agents, *J. Clin. Invest.* 104, 263-269.

Casenghi M, Mangiacasale R, Tuynder M, Caillet-Fauquet P, Elhajouji A, Lavia P, Mousset S, Kirsch-Volders M and Cundari E. (1999). p53-independent apoptosis and p53-dependent block of DNA rereplication following mitotic spindle inhibition in human cells, *Exp. Cell Res.* 250, 339-350.

Castedo M, Coquelle A, Vivet S, Vitale I, Kauffmann A, Dessen P, Pequignot MO, Casares N, Valent A, Mouhamad S, Schmitt E, Modjtahedi N, Vainchenker W, Zitvogel L, Lazar V, Garrido C and Kroemer G. (2006). Apoptosis regulation in tetraploid cancer cells, *EMBO J.* 25, 2584-2595.

Castedo M, Perfettini JL, Roumier T, Andreau K, Medema R and Kroemer G. (2004a). Cell death by mitotic catastrophe: a molecular definition, *Oncogene* 23, 2825-2837.

Castedo M, Perfettini JL, Roumier T, Valent A, Raslova H, Yakushijin K, Horne D, Feunteun J, Lenoir G, Medema R, Vainchenker W and Kroemer G. (2004b). Mitotic catastrophe constitutes a special case of apoptosis whose suppression entails aneuploidy, *Oncogene* 23, 4362-4370.

Castedo M, Perfettini JL, Roumier T, Yakushijin K, Horne D, Medema R and Kroemer G. (2004c). The cell cycle checkpoint kinase Chk2 is a negative regulator of mitotic catastrophe, *Oncogene* 23, 4353-4361.

Collins K, Jacks T and Pavletich NP. (1997). The cell cycle and cancer, *Proc. Natl. Acad. Sci. U S A* 94, 2776-2778.

Cossarizza A and Salvioli S. (2001). Analysis of mitochondria during cell death, *Methods Cell Biol.* 63, 467-486.

Chabner BA and Longo DL. (2001). *Cancer Chemotherapy and Biotherapy: Principles and Practice*. Lippincott-Williams & Wilkins: Philadelphia, PA, 3rd edition.

Chang B-D, Swift ME, Shen M, Fang J, Broude EV and Roninson IB. (2002). Molecular determinants of terminal growth arrest induced in tumor cells by a chemotherapeutic agent, *Proc. Natl. Acad. Sci. USA* 99, 389-394.

Chang BD, Broude EV, Dokmanovic M, Zhu H, Ruth A, Xuan Y, Kandel ES, Lausch E, Christov K and Roninson IB. (1999a). A senescence-like phenotype distinguishes tumor cells that undergo terminal proliferation arrest after exposure to anticancer agents, *Cancer Res.* 59, 3761-3767.

Chang BD, Broude EV, Fang J, Kalinichenko TV, Abdryashitov R, Poole JC and Roninson IB. (2000). p21^{Waf1/Cip1/Sdi1}-induced growth arrest is associated with depletion of mitosis-control proteins and leads to abnormal mitosis and endoreduplication in recovering cells, *Oncogene* 19, 2165-2170.

Chang BD, Xuan Y, Broude EV, Zhu H, Schott B, Fang J and Roninson IB. (1999b). Role of p53 and p21^{waf1/cip1} in senescence-like terminal proliferation arrest induced in human tumor cells by chemotherapeutic drugs, *Oncogene* 18, 4808-4818.

Chu K, Teele N, Dewey MW, Albright N and Dewey WC. (2004). Computerized video time lapse study of cell cycle delay and arrest, mitotic catastrophe, apoptosis and

clonogenic survival in irradiated 14-3-3 σ and CDKN1A (p21) knockout cell lines, *Radiat Res.* 162, 270-86.

de Bruin EC and Medema JP. (2008). Apoptosis and non-apoptotic deaths in cancer development and treatment response, *Cancer Treat. Rev.* 34, 737-749.

Demidenko ZN, Kalurupalle S, Hanco C, Lim CU, Broude E and Blagosklonny MV. (2008). Mechanism of G1-like arrest by low concentrations of paclitaxel: next cell cycle p53-dependent arrest with sub G1 DNA content mediated by prolonged mitosis, *Oncogene* 27, 4402-4410.

DeVita VTJr, Hellman S and Rosenberg SA. (2005). *Cancer: Principles & Practice of Oncology*. Lippincott Williams & Wilkins: Philadelphia, PA, 2nd edition.

Dimri GP, Lee X, Basile G, Acosta M, Scott G, Roskelley C, Medrano EE, Linskens M, Rubelj I, Pereira-Smith O, Peacocke M and Campisi J. (1995). A biomarker that identifies senescent human cells in culture and in aging skin in vivo, *Proc. Natl. Acad. Sci. USA* 92, 9363-9367.

Donehower LA. (2002). Does p53 affect organismal aging?, *J. Cell Physiol.* 192, 23-33.

Doyle A, Griffiths JB and Newell DG. (1995). *Cell & Tissue Culture: Laboratory procedures*. John Wiley & sons: New York.

Duverger V, Murphy AM, Sheehan D, England K, Cotter TG, Hayes I and Murphy FJ. (2004). The anticancer drug mithramycin A sensitises tumour cells to apoptosis induced by tumour necrosis factor (TNF), *Br. J. Cancer* 90, 2025-2031.

El-Deiry WS. (2003). The role of p53 in chemosensitivity and radiosensitivity, *Oncogene* 22, 7486-7495.

El-Deiry WS, Tokino T, Velculescu VE, Levy DB, Parsons R, Trent JM, Lin D, Mercer WE, Kinzler KW and Vogelstein B. (1993). WAF1, a potential mediator of p53 tumor suppression, *Cell* 75, 817-25.

Elmore LW, Rehder CW, Di X, McChesney PA, Jackson-Cook CK, Gewirtz DA and Holt SE. (2002). Adriamycin-induced senescence in breast tumor cells involves functional p53 and telomere dysfunction, *J. Biol. Chem.* 277, 35509-35515.

Enders GH. (2008). Expanded roles for Chk1 in genome maintenance, *J. Biol. Chem.* 283, 17749-17752.

Eom YW, Kim MA, Park SS, Goo MJ, Kwon HJ, Sohn S, Kim WH, Yoon G and Choi KS. (2005). Two distinct modes of cell death induced by doxorubicin: apoptosis and cell death through mitotic catastrophe accompanied by senescence-like phenotype, *Oncogene* 24, 4765-4777.

Erenpreisa J, Kalejs M and Cragg MS. (2005). Mitotic catastrophe and endomitosis in tumour cells: An evolutionary key to a molecular solution, *Cell Biol. Int.* 29, 1012-1018.

Ferlay J, Autier P, Boniol M, Heanue M, Colombet M and Boyle P. (2007). Estimates of the cancer incidence and mortality in Europe in 2006, *Ann. Oncol.* 18, 581-592.

Fernández E, Lombó F, Méndez C and Salas JA. (1996). An ABC transporter is essential for resistance to the antitumor agent mithramycin in the producer *Streptomyces argillaceus*, *Mol. Gen. Genet.* 251, 692-698.

Fernández E, Weissbach U, Sánchez Reillo C, Braña AF, Méndez C, Rohr J and Salas JA. (1998). Identification of two genes from *Streptomyces argillaceus* encoding glycosyltransferases involved in transfer of a disaccharide during biosynthesis of the antitumor drug mithramycin, *J. Bacteriol.* 180, 4929-4937.

Ferrante RJ, Ryu H, Kubilus JK, D'Mello S, Sugars KL, Lee J, Lu P, Smith K, Browne S, Beal MF, Kristal BS, Stavrovskaya IG, Hewett S, Rubinsztein DC, Langley B and

Ratan RR. (2004). Chemotherapy for the brain: the antitumor antibiotic mithramycin prolongs survival in a mouse model of Huntington's disease, *J. Neurosci.* 24, 10335-10342.

Fibach E, Bianchi N, Borgatti M, Prus E and Gambari R. (2003). Mithramycin induces fetal hemoglobin production in normal and thalassemic human erythroid precursor cells, *Blood* 102, 1276-81.

Fischer PM. (2004). The use of CDK inhibitors in oncology: a pharmaceutical perspective, *Cell Cycle* 3, 742-746.

Gartel AL and Shchors K. (2003). Mechanisms of c-myc-mediated transcriptional repression of growth arrest genes, *Exp. Cell Res.* 283, 17-21.

Gewirtz DA, Holt SE and Elmore LW. (2008). Accelerated senescence: an emerging role in tumor cell response to chemotherapy and radiation, *Biochem. Pharmacol.* 76, 947-957.

Giono LE and Manfredi JJ. (2006). The p53 tumor suppressor participates in multiple cell cycle checkpoints, *J. Cell Physiol.* 209, 13-20.

Golstein P and Kroemer G. (2007). Cell death by necrosis: towards a molecular definition, *Trends Biochem. Sci.* 32, 37-43.

Gottesman MM, Fojo T and Bates SE. (2002). Multidrug resistance in cancer: role of ATP-dependent transporters, *Nature Rev. Cancer* 2, 48-58.

Greenblatt MS, Bennett WP, Hollstein M and Harris CC. (1994). Mutations in the p53 tumor suppressor gene: clues to cancer etiology and molecular pathogenesis, *Cancer Res.* 54, 4855-4878.

Grinstein E, Jundt F, Weinert I, Wernet P and Royer HD. (2002). Sp1 as G1 cell cycle phase specific transcription factor in epithelial cells, *Oncogene* 21, 1485-1492.

- Hengartner MO. (2000). The biochemistry of apoptosis, *Nature* 407, 770-776.
- Hernández-Vargas H, Palacios J and Moreno-Bueno G. (2007). Telling cells how to die: docetaxel therapy in cancer cell lines, *Cell Cycle* 6, 780-783.
- Huang X, Tran T, Zhang L, Hatcher R and Zhang P. (2005). DNA damage-induced mitotic catastrophe is mediated by the Chk1-dependent mitotic exit DNA damage checkpoint, *Proc. Natl. Acad. Sci. USA* 102, 1065-1070.
- Hwang CK, Kim HS, Hong YS, Kim YH, Hong SK, Kim SJ and Lee JJ. (1995). Expression of *Streptomyces peucetius* genes for doxorubicin resistance and aklavinone 11-hydroxylase in *Streptomyces galilaeus* ATCC 31133 and production of a hybrid aclacinomycin, *Antimicrob. Agents Chemother.* 39, 1616-1620.
- Jaattela M and Tschopp J. (2003). Caspase-independent cell death in T lymphocytes, *Nat. Immunol.* 4, 416-423.
- Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T and Thun MJ. (2008). Cancer statistics, 2008, *CA Cancer J. Clin.* 58, 71-96.
- Jia Z, Zhang J, Wei D, Wang L, Yuan P, Le X, Li Q, Yao J and Xie K. (2007). Molecular basis of the synergistic antiangiogenic activity of bevacizumab and mithramycin A, *Cancer Res.* 67, 4878-4885.
- Johnstone RW, Ruefli AA and Lowe SW. (2002). Apoptosis: a link between cancer genetics and chemotherapy, *Cell* 108, 153-164.
- Koutsodontis G and Kardassis D. (2004). Inhibition of p53-mediated transcriptional responses by mithramycin A, *Oncogene* 23, 9190-9200.
- Kroemer G, Galluzzi L, Vandenabeele P, Abrams J, Alnemri ES, Baehrecke EH, Blagosklonny MV, El-Deiry WS, Golstein P, Green DR, Hengartner M, Knight RA, Kumar S, Lipton SA, Malorni W, Nunez G, Peter ME, Tschopp J, Yuan J, Piacentini M,

Zhivotovsky B and Melino G. (2009). Classification of cell death: recommendations of the Nomenclature Committee on Cell Death 2009, *Cell Death Differ* 16, 3-11.

Krumschnabel G, Sohm B, Bock F, Manzl C and Villunger A. (2009). The enigma of caspase-2: the laymen's view, *Cell Death Differ*. 16, 195-207.

Künzel E, Wohlert S, Beninga C, Haag S, Decker H, Hutchinson CR, Blanco G, Mendez C, Salas JA and Rohr J. (1997). Tetracenomycin M, a novel genetically engineered tetracenomycin resulting from a combination of mithramycin and tetracenomycin biosynthetic genes, *Chem. Eur. J.* 3, 1675-1678.

Levesque AA and Eastman A. (2007). p53-based cancer therapies: Is defective p53 the Achilles heel of the tumor?, *Carcinogenesis* 28, 13-20.

Li J and Yuan J. (2008). Caspases in apoptosis and beyond, *Oncogene* 27, 6194-6206.

Lodish H, Berk A, Zipursky LS, Matsudaira P, Baltimore D and Darnell J. (2000). *Molecular Cell Biology*. W. H. Freeman & Co.: New York, 4th edition.

Lowe SW, Bodis S, McClatchey A, Remington L, Ruley HE, Fisher DE, Housman DE and Jacks T. (1994). p53 status and the efficacy of cancer therapy *in vivo*, *Science* 266, 807-810.

Malumbres M and Barbacid M. (2009). Cell cycle, CDKs and cancer: a changing paradigm, *Nat. Rev. Cancer* 9, 153-166.

Mansilla S, Bataller M and Portugal J. (2006a). Mitotic catastrophe as a consequence of chemotherapy, *Anticancer Agents Med. Chem.* 6, 589-602.

Mansilla S, Piña B and Portugal J. (2003). Daunorubicin-induced variations in gene transcription: commitment to proliferation arrest, senescence and apoptosis, *Biochem. J.* 372, 703-711.

Mansilla S and Portugal J. (2008). Sp1 transcription factor as a target for anthracyclines: effects on gene transcription, *Biochimie* 90, 976-987.

Mansilla S, Priebe W and Portugal J. (2006b). Mitotic catastrophe results in cell death by caspase-dependent and caspase-independent mechanisms, *Cell Cycle* 5, 53-60.

Mansilla S, Priebe W and Portugal J. (2006c). Transcriptional changes facilitate mitotic catastrophe in tumour cells that contain functional p53, *Eur. J. Pharmacol.* 540, 34-45.

Meulmeester E and Jochemsen AG. (2008). p53: a guide to apoptosis, *Curr. Cancer Drug Targets* 8, 87-97.

Mosmann T. (1983). Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays, *J. Immunol. Methods* 65, 55-63.

Niquet J, Allen SG, Baldwin RA and Wasterlain CG. (2004). Evidence of caspase-3 activation in hyposmotic stress-induced necrosis, *Neurosci. Lett.* 356, 225-227.

Niquet J, Auvin S, Archie M, Seo DW, Allen S, Sankar R and Wasterlain CG. (2007). Status epilepticus triggers caspase-3 activation and necrosis in the immature rat brain, *Epilepsia* 48, 1203-1206.

Parish CR. (1999). Fluorescent dyes for lymphocyte migration and proliferation studies, *Immunol. Cell. Biol.* 77, 499-508.

Peñuelas S, Alemany C, Noé V and Ciudad CJ. (2003). The expression of retinoblastoma and Sp1 is increased by low concentrations of cyclin-dependent kinase inhibitors, *Eur J Biochem* 270, 4809-4822.

Phillips A, Darley M and Blaydes JP. (2006). GC-selective DNA-binding antibiotic, mithramycin A, reveals multiple points of control in the regulation of Hdm2 protein synthesis, *Oncogene* 25, 4183-4193.

Previdi S, Albertini V, Nur-e-Alam M, Kwee I, Broggin M, Carbone GM, Rohr J and Catapano CV. (2006). Antitumor activity of the new aureolic acid derivatives mithramycin SDK and SK in human ovarian cancer xenografts, *Eur. J. Cancer Supplement 4*, 97 (a308).

Remsing LL, Bahadori HR, Carbone GM, McGuffie EM, Catapano CV and Rohr J. (2003a). Inhibition of c-src transcription by mithramycin: structure-activity relationships of biosynthetically produced mithramycin analogues using the c-src promoter as target, *Biochemistry* 42, 8313-8324.

Remsing LL, González AM, Nur-e-Alam M, Fernández-Lozano MJ, Braña AF, Rix U, Oliveira MA, Méndez C, Salas JA and Rohr J. (2003b). Mithramycin SK, a novel antitumor drug with improved therapeutic index, mithramycin SA, and demycarosyl-mithramycin SK: three new products generated in the mithramycin producer *Streptomyces argillaceus* through combinatorial biosynthesis, *J. Am. Chem. Soc.* 125, 5745-5753.

Ricci MS and Zong WX. (2006). Chemotherapeutic approaches for targeting cell death pathways, *Oncologist* 11, 342-357.

Rohr J, Weißbach U, Beninga C, Künzel E, Siems K, Bindseil KU, Lombó F, Prado L, Braña AF, Méndez C and Salas JA. (1998). The structures of premithramycinone and demethylpremithramycinone, plausible early intermediates of the aureolic acid group antibiotic mithramycin, *Chem. Commun.*, 437-438.

Roninson IB. (2002). Tumor senescence as a determinant of drug response in vivo, *Drug Resist. Updat.* 5, 204-208.

Roninson IB, Broude EV and Chang B-D. (2001). If not apoptosis, then what? Treatment-induced senescence and mitotic catastrophe in tumor cells, *Drug Resist. Updat.* 4, 303-313.

Salas JA and Méndez C. (1998). Genetic manipulation of antitumor-agent biosynthesis to produce novel drugs, *Trends Biotechnol.* 16, 475-482.

Sambrook J, Fritsch EF and Maniatis T. (1989). *Molecular Cloning. A laboratory manual*. Cold Spring Harbour Lab.: New York.

Schmitt CA. (2007). Cellular senescence and cancer treatment, *Biochim Biophys Acta* 1775, 5-20.

Shay JW and Roninson IB. (2004). Hallmarks of senescence in carcinogenesis and cancer therapy, *Oncogene* 23, 2919-2933.

Shay JW and Wright WE. (2005). Senescence and immortalization: role of telomeres and telomerase, *Carcinogenesis* 26, 867-874.

Sheldon PJ, Johnson DA, August PR, Liu HW and Sherman DH. (1997). Characterization of a mitomycin-binding drug resistance mechanism from the producing organism, *Streptomyces lavendulae*, *J. Bacteriol.* 179, 1796-1804.

Sidi S, Sanda T, Kennedy RD, Hagen AT, Jette CA, Hoffmans R, Pascual J, Imamura S, Kishi S, Amatruda JF, Kanki JP, Green DR, D'Andrea AA and Look AT. (2008). Chk1 suppresses a caspase-2 apoptotic response to DNA damage that bypasses p53, Bcl-2, and caspase-3, *Cell* 133, 864-877.

Smits VA and Medema RH. (2001). Checking out the G(2)/M transition, *Biochim. Biophys. Acta* 1519, 1-12.

Storchova Z and Pellman D. (2004). From polyploidy to aneuploidy, genome instability and cancer, *Nat. Rev. Mol. Cell Biol.* 5, 45-54.

Tapias A, Ciudad CJ, Roninson IB and Noé V. (2008). Regulation of Sp1 by cell cycle related proteins, *Cell Cycle* 7, 2856-2867.

te Poele RH, Okorokov AL, Jardine L, Cummings J and Joel SP. (2002). DNA damage is able to induce senescence in tumor cells in vitro and in vivo, *Cancer Res.* 62, 1876-1883.

Toettcher JE, Loewer A, Ostheimer GJ, Yaffe MB, Tidor B and Lahav G. (2009). Distinct mechanisms act in concert to mediate cell cycle arrest, *Proc. Natl. Acad. Sci. U S A* 106, 785-790.

Toiyama Y, Tanaka K, Konishi N, Mohri Y, Tonouchi H, Miki C and Kusunoki M. (2006). Administration sequence-dependent antitumor effects of paclitaxel and 5-fluorouracil in the human gastric cancer cell line MKN45, *Cancer Chemother. Pharmacol.* 57, 368-75.

Tsugu A, Sakai K, Dirks PB, Jung S, Weksberg R, Fei YL, Mondal S, Ivanchuk S, Ackerley C, Hamel PA and Rutka JT. (2000). Expression of p57(KIP2) potently blocks the growth of human astrocytomas and induces cell senescence, *Am J Pathol* 157, 919-932.

Vakifahmetoglu H, Olsson M, Tamm C, Heidari N, Orrenius S and Zhivotovsky B. (2008a). DNA damage induces two distinct modes of cell death in ovarian carcinomas, *Cell Death Differ* 15, 555-566.

Vakifahmetoglu H, Olsson M and Zhivotovsky B. (2008b). Death through a tragedy: mitotic catastrophe, *Cell Death Differ.* 15, 1153-1162.

Verheij M. (2008). Clinical biomarkers and imaging for radiotherapy-induced cell death, *Cancer Metastasis Rev.* 27, 471-480.

Vermes I, Haanen C, Steffens-Nakken H and Reutelingsperger C. (1995). A novel assay for apoptosis. Flow cytometric detection of phosphatidylserine expression on early apoptotic cells using fluorescein labelled Annexin V, *J. Immunol. Methods* 184, 39-51.

Vigneron A, Roninson IB, Gamelin E and Coqueret O. (2005). Src inhibits adriamycin-induced senescence and G2 checkpoint arrest by blocking the induction of p21waf1, *Cancer Res.* 65, 8927-8935.

Villamarín S, Ferrer-Miralles N, Mansilla S, Priebe W and Portugal J. (2002). Induction of G2/M arrest and inhibition of *c-myc* and *p53* transcription by WP631 in Jurkat T cells, *Biochem. Pharmacol.* 63, 1251-1258.

Vogel C, Hager C and Bastians H. (2007). Mechanisms of mitotic cell death induced by chemotherapy-mediated G2 checkpoint abrogation, *Cancer Res* 67, 339-345.

Vogel C, Kienitz A, Hofmann I, Muller R and Bastians H. (2004). Crosstalk of the mitotic spindle assembly checkpoint with p53 to prevent polyploidy, *Oncogene* 23, 6845-53.

Vogelstein B and Kinzler KW. (2004). Cancer genes and the pathways they control, *Nature Med.* 10, 789-799.

Wang L, Guan X, Zhang J, Jia Z, Wei D, Li Q, Yao J and Xie K. (2008). Targeted inhibition of Sp1-mediated transcription for antiangiogenic therapy of metastatic human gastric cancer in orthotopic nude mouse models, *Int. J. Oncol.* 33, 161-167.

Wei D, Wang L, He Y, Xiong HQ, Abbruzzese JL and Xie K. (2004). Celecoxib inhibits vascular endothelial growth factor expression in and reduces angiogenesis and metastasis of human pancreatic cancer via suppression of Sp1 transcription factor activity, *Cancer Res.* 64, 2030-2038.

Weinstein JN, Myers TG, OConnor PM, Friend SH, Fornace AJ, Kohn KW, Fojo T, Bates SE, Rubinstein LV, Anderson NL, Buolamwini JK, vanOsdol WW, Monks AP, Scudiero DA, Sausville EA, Zaharevitz DW, Bunow B, Viswanadhan VN, Johnson GS, Wittes RE and Paull KD. (1997). An information-intensive approach to the molecular pharmacology of cancer, *Science* 275, 343-349.

Weller M. (1998). Predicting response to cancer chemotherapy: the role of p53, *Cell Tissue Res.* 292, 435-445.

White E. (1996). Life, death, and the pursuit of apoptosis, *Genes Dev.* 10, 1-15.

Yashige H, Horiike S, Taniwaki M, Misawa S and Abe T. (1999). Micronuclei and nuclear abnormalities observed in erythroblasts in myelodysplastic syndromes and in de novo acute leukemia after treatment, *Acta Haematol.* 101, 32-40.

Zajac M, Moneo MV, Carnero A, Benitez J and Martinez-Delgado B. (2008). Mitotic catastrophe cell death induced by heat shock protein 90 inhibitor in BRCA1-deficient breast cancer cell lines, *Mol. Cancer Ther.* 7, 2358-2366.

Zhivotovsky B. (2004). Apoptosis, necrosis and between, *Cell Cycle* 3, 64-66.

Zong WX, Ditsworth D, Bauer DE, Wang ZQ and Thompson CB. (2004). Alkylating DNA damage stimulates a regulated form of necrotic cell death, *Genes Dev.* 18, 1272-1282.

